Department of Rehabilitation, Exercise, and Nutritional Sciences, University of Cincinnati College of Allied Health Sciences, Cincinnati, OH, USA.
Department of Neonatology, Banner University Medical Center, The University of Arizona, Tucson, AZ, USA.
J Nutr. 2022 Jun 9;152(6):1404-1414. doi: 10.1093/jn/nxac043.
In a randomized trial of DHA supplementation to lactating mothers who delivered preterm, there were significant increases in DHA status in the mother and her infant.
Our objective here was to characterize the mammary gland transcriptomes from the above study. We hypothesized that proinflammatory gene expression would be attenuated in the increased DHA group compared with the standard DHA group.
In the original trial, mothers delivering at <29 wk gestation at the University of Cincinnati Medical Center and intending to express their milk were randomly assigned to supplementation with 200 mg/d DHA (standard group: STD) or 1000 mg/d DHA (experimental group: EXP) within 7 d of delivery. Here, we conducted RNA-seq transcriptome analysis of n = 5 EXP and n = 4 STD extracellular mammary mRNA samples extracted from the fat layer of milk samples obtained 4 wk postenrollment. Transcripts were assessed for differential expression (false discovery rate adjusted P value <0.05) and clustering between EXP compared with STD groups. Ontological analysis of all differentially expressed genes (DEGs) was performed with Toppcluster.
There were 409 DEGs. We observed 5 main groups of biological processes that were upregulated, including those associated with improved immune regulation and management of oxidative stress; and 3 main groups of biological processes that were downregulated, including 1 associated with immune dysregulation. For example, we observed upregulation of inflammation-inhibiting genes including NFKB inhibitor alpha (NFKBIA; fold-change (FC), adjusted P value: FC = 1.70, P = 0.007) and interleukin-18 binding protein (IL18BP: FC = 2.2, adjusted P = 0.02); and downregulation of proinflammatory genes including interleukin 7 receptor (IL7R: FC = -1.9, adjusted P = 0.02) and interleukin 1 receptor like 1 (IL1RL1: FC = -13.0, adjusted P = 0.02).
Increased DHA supplementation during lactation can modulate the expression of inflammation-related genes within the mammary gland. This might translate to milk composition with a more optimal inflammasome profile. Future research with a larger clinical trial and greater interrogation of clinical outcomes is warranted.
在一项针对早产儿哺乳期母亲补充 DHA 的随机试验中,母亲和婴儿的 DHA 状况均显著增加。
本研究旨在对上述研究中的乳腺转录组进行特征描述。我们假设与标准 DHA 组相比,增加 DHA 组的促炎基因表达会减弱。
在最初的试验中,辛辛那提大学医疗中心分娩时孕周<29 周并打算母乳喂养的母亲在分娩后 7 天内随机分配补充 200mg/d DHA(标准组:STD)或 1000mg/d DHA(实验组:EXP)。在这里,我们对 n = 5 EXP 和 n = 4 STD 从产后 4 周收集的母乳样本脂肪层中提取的细胞外乳腺 mRNA 样本进行了 RNA-seq 转录组分析。评估差异表达(错误发现率调整的 P 值<0.05)和 EXP 与 STD 组之间的聚类。使用 Toppcluster 对所有差异表达基因(DEGs)进行了本体论分析。
有 409 个 DEGs。我们观察到 5 个主要的生物学过程上调组,包括与改善免疫调节和氧化应激管理相关的生物学过程;和 3 个下调的生物学过程组,包括 1 个与免疫失调相关的生物学过程组。例如,我们观察到炎症抑制基因的上调,包括 NFKB 抑制剂 alpha(NFKBIA;倍数变化(FC),调整 P 值:FC = 1.70,P = 0.007)和白细胞介素 18 结合蛋白(IL18BP:FC = 2.2,调整 P = 0.02);和促炎基因的下调,包括白细胞介素 7 受体(IL7R:FC = -1.9,调整 P = 0.02)和白细胞介素 1 受体样 1(IL1RL1:FC = -13.0,调整 P = 0.02)。
哺乳期增加 DHA 补充可以调节乳腺中与炎症相关的基因表达。这可能转化为具有更理想的炎症小体谱的乳汁成分。需要进行更大规模的临床试验和更深入的临床结局研究来验证这一发现。